{"title":"Drawing lines: how the public defines “Serious” genetic conditions for reproductive testing","authors":"Shizuko Takahashi, Rie Iizuka, Serene Ong, Tianxiang Lan, Tsutomu Sawai","doi":"10.1038/s41431-026-02170-2","DOIUrl":null,"url":null,"abstract":"Prior normative and empirical research has identified a gap between how patients and the public conceptualize “serious” conditions eligible for preimplantation genetic testing for monogenic disorders (PGT-M) and how seriousness is defined. Japan represents a highly restrictive regulatory context shaped by its historical experience with eugenics. Although PGT-M has been available since 1998, its use has been tightly limited, with the first birth occurring six years later and approximately 36 conditions approved to date. This study examines how Japanese adults of reproductive age understand “seriousness” in genetic disease and how they view PGT-M in relation to concerns about eugenic selection (inochi no senbetsu, “sorting of lives”). We conducted a cross-sectional online survey of 458 adults aged 18–42 years. Measures included perceived seriousness across clinical parameters (penetrance, survival, daily life impact), willingness to use PGT-M, perceived barriers to access, and attitudes toward eugenic selection. Awareness of PGT-M was low (12%), yet 44% of participants would consider its use. Participants defined seriousness more broadly than current Japanese policy permits: most rated highly penetrant or childhood-lethal conditions as serious, and over half also included conditions associated with mild to moderate functional limitations. Participants distinguished disease prevention from enhancement. Economic burden was the most frequently cited barrier (70%). Many participants who expressed ethical discomfort with eugenic selection nonetheless reported willingness to consider PGT-M. These findings reveal a substantial gap between policy, public reasoning, and reproductive preferences, with implications for European debates on seriousness and proportionality in reproductive genetic testing.","PeriodicalId":12016,"journal":{"name":"European Journal of Human Genetics","volume":"34 10","pages":"1538-1546"},"PeriodicalIF":4.6000,"publicationDate":"2026-07-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.nature.comhttps://www.nature.com/articles/s41431-026-02170-2.pdf","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"European Journal of Human Genetics","FirstCategoryId":"99","ListUrlMain":"https://www.nature.com/articles/s41431-026-02170-2","RegionNum":2,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"BIOCHEMISTRY & MOLECULAR BIOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Prior normative and empirical research has identified a gap between how patients and the public conceptualize “serious” conditions eligible for preimplantation genetic testing for monogenic disorders (PGT-M) and how seriousness is defined. Japan represents a highly restrictive regulatory context shaped by its historical experience with eugenics. Although PGT-M has been available since 1998, its use has been tightly limited, with the first birth occurring six years later and approximately 36 conditions approved to date. This study examines how Japanese adults of reproductive age understand “seriousness” in genetic disease and how they view PGT-M in relation to concerns about eugenic selection (inochi no senbetsu, “sorting of lives”). We conducted a cross-sectional online survey of 458 adults aged 18–42 years. Measures included perceived seriousness across clinical parameters (penetrance, survival, daily life impact), willingness to use PGT-M, perceived barriers to access, and attitudes toward eugenic selection. Awareness of PGT-M was low (12%), yet 44% of participants would consider its use. Participants defined seriousness more broadly than current Japanese policy permits: most rated highly penetrant or childhood-lethal conditions as serious, and over half also included conditions associated with mild to moderate functional limitations. Participants distinguished disease prevention from enhancement. Economic burden was the most frequently cited barrier (70%). Many participants who expressed ethical discomfort with eugenic selection nonetheless reported willingness to consider PGT-M. These findings reveal a substantial gap between policy, public reasoning, and reproductive preferences, with implications for European debates on seriousness and proportionality in reproductive genetic testing.
先前的规范和实证研究已经确定了患者和公众如何概念化有资格进行单基因疾病植入前基因检测(PGT-M)的“严重”疾病与如何定义严重性之间的差距。日本在优生学方面的历史经验形成了高度限制性的监管环境。尽管PGT-M自1998年以来就已经可用,但其使用受到严格限制,第一次分娩发生在6年后,迄今为止大约有36种情况获得批准。这项研究调查了日本育龄成年人如何理解遗传疾病的“严重性”,以及他们如何看待PGT-M与优生选择(inochi no senbetsu,“生命分类”)的关系。我们对458名18-42岁的成年人进行了横断面在线调查。测量包括临床参数的感知严重性(外显率、生存率、日常生活影响)、使用PGT-M的意愿、感知到的获取障碍以及对优生选择的态度。对PGT-M的认识很低(12%),但44%的参与者会考虑使用它。参与者对严重性的定义比目前日本政策允许的范围更广:大多数人认为高度渗透或儿童致命的疾病是严重的,超过一半的人还包括与轻度到中度功能限制相关的疾病。参与者区分了疾病预防和增强。经济负担是最常被提及的障碍(70%)。许多对优生选择表示道德上的不适的参与者仍然表示愿意考虑PGT-M。这些发现揭示了政策、公众推理和生殖偏好之间的巨大差距,这对欧洲关于生殖基因检测的严谨性和比例性的辩论产生了影响。
期刊介绍:
The European Journal of Human Genetics is the official journal of the European Society of Human Genetics, publishing high-quality, original research papers, short reports and reviews in the rapidly expanding field of human genetics and genomics. It covers molecular, clinical and cytogenetics, interfacing between advanced biomedical research and the clinician, and bridging the great diversity of facilities, resources and viewpoints in the genetics community.
Key areas include:
-Monogenic and multifactorial disorders
-Development and malformation
-Hereditary cancer
-Medical Genomics
-Gene mapping and functional studies
-Genotype-phenotype correlations
-Genetic variation and genome diversity
-Statistical and computational genetics
-Bioinformatics
-Advances in diagnostics
-Therapy and prevention
-Animal models
-Genetic services
-Community genetics